Our lab focuses on developing innovative therapeutic strategies to address the high mortality associated with solid tumors (lung cancer, ovarian cancer, and melanoma). A significant proportion of patients are diagnosed at metastatic stages, where conventional therapies often fail due to resistance mechanisms and an immunosuppressive tumor microenvironment. To overcome these challenges, our research aims to transform the tumor microenvironment to enhance responsiveness to immunotherapy. We are particularly interested in synthetic cellular engineering approaches that enable precise modulation of immune responses. Our current efforts center on:
Engineering mesenchymal stem cells (MSCs) as delivery vehicles for immunomodulatory agents.
– Localized cytokine delivery to minimize systemic toxicity and maximize therapeutic efficacy.
– Targeting myeloid-derived suppressor cells (MDSCs) to disrupt the immunosuppressive premetastatic niche.
– Enhancing immune checkpoint blockade therapies by reprogramming the tumor microenvironment to support anti-tumor immunity.
By integrating principles of molecular engineering, nanotechnology, and immunobiology, we aim to redefine the treatment landscape for lung cancer, particularly for patients with advanced, therapy-resistant disease. Our long-term goal is to develop personalized, cell-based immunotherapies that are both effective and safe, contributing to improved outcomes and quality of life for patients.